NEW YORK (GenomeWeb) – Invivoscribe Technologies announced today that it has submitted a pre-market approval application with Japan's Pharmaceutical and Medical Devices Agency, as well as a panel track supplement to the US Food and Drug Administration for its LeukoStrat CDx FLT3 Mutation assay.